Clinical Trial

Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial studies how well ibrutinib and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back or has not responded to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells. Giving ibrutinib and nivolumab may work better in treating patients with classical Hodgkin lymphoma.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2016-10-18; most recent amendment 2026-02-12.
Status change: Suspended → Active, Not Recruiting 2021-03-23
Status change: Recruiting → Suspended 2021-03-01
Status change: Not Yet Recruiting → Recruiting 2016-12-20
Trial Details
NCT Number NCT02940301
Lead Sponsor Ohio State University Comprehensive Cancer Center
Conditions Classical Hodgkin Lymphoma
Enrollment 18 participants
Start Date 2016-12-20
Primary Completion 2026-08-15 (estimated)
Study Completion 2026-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-17